AF
INSY

Allworth Financial’s Insys Therapeutics, Inc. INSY Stock Holding History

Allworth Financial’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,246
Closed -$16K – 824
2017
Q2 		$16K Buy
+1,246
New +$14.7K ﹤0.01% 414

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allworth Financial's INSY Position: Q3 2017 in Review

Allworth Financial sold out of Insys Therapeutics, Inc. (INSY) in Q3 2017, closing a stake of 1,246 shares — an estimated $16K sold.

Allworth Financial first reported a position in INSY in Q2 2017 and held it in 1 quarter. The position peaked at $16K in Q2 2017. 116 funds tracked by Wall St. Rank hold INSY as of Q3 2017.

  • Allworth Financial reported no remaining Insys Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Allworth Financial sold 1,246 Insys Therapeutics, Inc. shares in Q3 2017, an estimated $16K.
  • Allworth Financial first reported a position in Insys Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Allworth Financial's Insys Therapeutics, Inc. position peaked at $16K in Q2 2017.
  • 116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2017.

Based on Allworth Financial's 13F filing for Q3 2017, filed 12 Oct 2017.